Dizziness: A Possible Side Effect During Semaglutide Titration Semaglutide is a GLP-1, or glucagon-like peptide-1, agonist
The Congressional Budget Office (CBO) has been working to provide information to Congress on the potential for preventive medical carewhich could include obesity treatmentto save money
It is possible that this could improve tissue blood supply and temporarily reduce the effect of hypoxia on the entire body
Recent clinical studies seem to offer new hope for some conditions, such as age related macular degeneration and uveitis, they note, but with potential risks of severe, though rare, ocular complications, such as ION, for others. References: Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk by Moiz Lakhani, Abdullah Al-Ani, Marko Popovic, tienne Bnard-Sguin and Edward Margolin, 10 March 2026, British Journal of Ophthalmology